AERI Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Nov 2022 @ 22:00):

Stats
Tagesvolumen	1.22M
Durchschnittsvolumen	786 842
Marktkapitalisierung	0.00
EPS	$-0.560 ( Q3 \| 2022-11-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0 (Sector) 42.63 (Industry) 30.78
ATR14	$0.0770 (0.50%)

AERI 0.00%

ALVO 1.33%

ALVOW 6.79%

BDSI -0.09%

BFRIW -5.93%

CLVRW 0.00%

CYTHW -4.35%

ENDP 0.00%

GRVI 7.61%

HPCO 0.06%

INDV -1.59%

JUPWW -20.00%

LFCR -0.19%

LNDC -3.52%

LSDI -23.29%

PRFX -3.65%

PROCW 10.09%

QLI 6.82%

SBFMW 0.00%

SHOT 9.43%

SHPH 4.28%

Insider Trading

Date	Person	Action	Amount	type
2022-11-21	Mchugh Julie	Sell	16 854	Stock Option (right to buy)
2022-11-21	Mcgraw Benjamin F Iii	Sell	16 854	Stock Option (right to buy)
2022-11-21	Mcdonnell Peter J	Sell	16 854	Stock Option (right to buy)
2022-11-21	Kopczynski Casey C.	Sell	65 941	Stock Option (right to buy)
2022-11-21	Lang Peter Frederick	Sell	160 551	Stock Option (right to buy)

INSIDER POWER
-99.57
Last 98 transactions
Buy: 1 757 162 \| Sell: 988 060

Volumen Korrelation

Lang: 0.16 (neutral)

Kurz: 0.47 (neutral)

Signal:(68.342) Neutral

Aerie Pharmaceuticals, Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Aerie Pharmaceuticals, Korrelation - Währung/Rohstoff

-0.81
( strong negative )

-0.94
( very strong negative )

-0.89
( strong negative )

-0.03
( neutral )

0.85
( strong )

0.70
( moderate )

Aerie Pharmaceuticals, Finanzdaten

Annual	2021
Umsatz:	$194.13M
Bruttogewinn:	$167.29M (86.17 %)
EPS:	$-1.610

FY	2021
Umsatz:	$194.13M
Bruttogewinn:	$167.29M (86.17 %)
EPS:	$-1.610

FY	2020
Umsatz:	$83.14M
Bruttogewinn:	$57.81M (69.53 %)
EPS:	$-3.99

FY	2019
Umsatz:	$69.89M
Bruttogewinn:	$65.06M (93.08 %)
EPS:	$-4.39

Financial Reports:

No articles found.

Aerie Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Aerie Pharmaceuticals,

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.